Last reviewed 2026-05-22 · How we verify

MRX-7EAT

MEDRx USA, Inc. · Phase 3 active Small molecule Under review

MRX-7EAT is a SGLT2 inhibitor Small molecule drug developed by MEDRx USA, Inc.. It is currently in Phase 3 development for Type 2 diabetes.

MRX-7EAT is a small molecule that targets the SGLT2 receptor.

MRX-7EAT is a topical patch being studied in clinical trials for the treatment of ankle sprains, bursitis, tendonitis, shoulder pain, and acute tendonitis. The exact mechanism of MRX-7EAT is currently unknown.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MRX-7EAT
Sponsor	MEDRx USA, Inc.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, MRX-7EAT reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Nausea
Diarrhea
Vomiting

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MRX-7EAT CI brief — competitive landscape report
MRX-7EAT updates RSS · CI watch RSS
MEDRx USA, Inc. portfolio CI

Frequently asked questions about MRX-7EAT

What is MRX-7EAT?

MRX-7EAT is a SGLT2 inhibitor drug developed by MEDRx USA, Inc., indicated for Type 2 diabetes.

How does MRX-7EAT work?

MRX-7EAT is a small molecule that targets the SGLT2 receptor.

What is MRX-7EAT used for?

MRX-7EAT is indicated for Type 2 diabetes.

Who makes MRX-7EAT?

MRX-7EAT is developed by MEDRx USA, Inc. (see full MEDRx USA, Inc. pipeline at /company/medrx-usa-inc).

What drug class is MRX-7EAT in?

MRX-7EAT belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is MRX-7EAT in?

MRX-7EAT is in Phase 3.

What are the side effects of MRX-7EAT?

Common side effects of MRX-7EAT include Nausea, Diarrhea, Vomiting.

What does MRX-7EAT target?

MRX-7EAT targets SGLT2 and is a SGLT2 inhibitor.

Drug class: All SGLT2 inhibitor drugs
Target: All drugs targeting SGLT2
Manufacturer: MEDRx USA, Inc. — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing